Effectiveness and Safety of Very-Low-Dose Rosuvastatin–Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study
Clinical Drug Investigation · 2025
DOI: 10.1007/s40261-025-01482-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Ji Woong Roh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Republic of Korea. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Ezetimibe, Dyslipidemias, Anticholesteremic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Hanmi Pharmaceutical.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Dyslipidaemia is a key modifiable risk factor for atherosclerotic cardiovascular disease. However, achieving recommended low-density lipoprotein cholesterol (LDL-C) target levels is challenging owing to dose-dependent adverse effects and limited tolerability of high-dose statins. This study evaluated the real-world efficacy and safety of combining very-low-dose rosuvastatin (2.5 mg) with ezetimibe (10 mg) in adult patients with dyslipidaemia across different cardiovascular risk strata. METHODS: This multicentre prospective study in South Korea enrolled 2,388 patients. Participants were stratified into low-, moderate-, or high-risk groups on the basis of the 2019 European Society of Cardiology and European Atherosclerosis Society guidelines. Lipid profiles and safety outcomes were assessed at baseline and after 12 weeks. The primary and secondary outcomes were LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) target level achievements, respectively, and adverse events were monitored. RESULTS: After 12 weeks, LDL-C target levels were achieved by 82.6% of low-risk (< 116 mg/dL), 73.9% of moderate-risk (< 100 mg/dL), and 50.4% of high-risk (< 70 mg/dL) patients. Non-HDL-C target level achievement followed a similar trend. Combination therapy with ezetimibe and low-dose statin resulted in significant LDL-C reductions, compared with statins alone. Adverse events were infrequent (0.6%), and only 0.2% of patients discontinued treatment owing to medication-related concerns. CONCLUSIONS: Very-low-dose rosuvastatin-ezetimibe combination therapy significantly lowered LDL-C levels and improved lipid profiles across various risk groups, demonstrating a favourable safety profile. These findings support its use as an effective, well-tolerated option for managing dyslipidaemia. Longer-term studies are warranted to evaluate sustained lipid control and cardiovascular outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Republic of Korea.
- Hanmi Pharmaceutical Co., Ltd., Seoul, Republic of Korea.
- Son Ji-Won Internal Medicine Clinic, Incheon, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Republic of Korea. cardiobsa@yuhs.ac.
Förderung
- Hanmi Pharmaceutical
Zitieren
APA
Roh, J. W., Park, M. H., Son, J. W., Bae, S., & HM-ROS-OS-2102 Study Investigator Group (2025). Effectiveness and Safety of Very-Low-Dose Rosuvastatin–Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01482-3
Vancouver
Roh JW, Park MH, Son JW, Bae S, HM-ROS-OS-2102 Study Investigator Group. Effectiveness and Safety of Very-Low-Dose Rosuvastatin–Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study. Clinical Drug Investigation. 2025. doi:10.1007/s40261-025-01482-3
BibTeX
@article{Roh2025,
author = {Roh, Ji Woong and Park, Moon-Hwa and Son, Ji-Won and Bae, SungA and HM-ROS-OS-2102 Study Investigator Group, HM-ROS-OS-2102 Study Investigator Group},
title = {Effectiveness and Safety of Very-Low-Dose Rosuvastatin–Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study},
journal = {Clinical Drug Investigation},
year = {2025},
doi = {10.1007/s40261-025-01482-3}
}
EUVIMED